Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Corticotropin. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Corticotropin. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Corticotropin. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Corticotropin. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Corticotropin. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Corticotropin. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Corticotropin. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Corticotropin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Corticotropin. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Corticotropin. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Corticotropin. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Corticotropin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Corticotropin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Corticotropin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Corticotropin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Corticotropin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Corticotropin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Corticotropin. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Corticotropin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Corticotropin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Corticotropin. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Corticotropin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Corticotropin. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Corticotropin. |
| Cladribine | Corticotropin may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Corticotropin. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Corticotropin. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Corticotropin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Corticotropin. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Corticotropin. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Corticotropin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Corticotropin. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Corticotropin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Corticotropin. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Corticotropin. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Corticotropin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Corticotropin. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Corticotropin. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Corticotropin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Corticotropin. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Corticotropin. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Corticotropin. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Corticotropin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Corticotropin. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Corticotropin. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Corticotropin. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Corticotropin. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Corticotropin. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Corticotropin. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Corticotropin. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Corticotropin. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Corticotropin. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Corticotropin. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Corticotropin. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Corticotropin. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Corticotropin. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Corticotropin. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Corticotropin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Corticotropin. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Corticotropin. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Corticotropin. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Corticotropin. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Corticotropin. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Corticotropin. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Corticotropin. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Corticotropin. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Corticotropin. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Corticotropin. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Corticotropin. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Corticotropin. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Corticotropin. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Corticotropin. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Corticotropin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Corticotropin. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Corticotropin. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Corticotropin. |
| Stepronin | The risk or severity of adverse effects can be increased when Corticotropin is combined with Stepronin. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Corticotropin is combined with Hydroxychloroquine. |
| Castanospermine | The risk or severity of adverse effects can be increased when Corticotropin is combined with Castanospermine. |
| Vorinostat | The risk or severity of adverse effects can be increased when Corticotropin is combined with Vorinostat. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when Corticotropin is combined with 2-Methoxyethanol. |
| Brequinar | The risk or severity of adverse effects can be increased when Corticotropin is combined with Brequinar. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Corticotropin is combined with Pirfenidone. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Corticotropin is combined with Interferon alfa. |
| Glatiramer | The risk or severity of adverse effects can be increased when Corticotropin is combined with Glatiramer. |
| Briakinumab | The risk or severity of adverse effects can be increased when Corticotropin is combined with Briakinumab. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Corticotropin is combined with Human interferon omega-1. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Corticotropin is combined with Mepolizumab. |
| Abetimus | The risk or severity of adverse effects can be increased when Corticotropin is combined with Abetimus. |
| Belatacept | The risk or severity of adverse effects can be increased when Corticotropin is combined with Belatacept. |
| Bendamustine | The risk or severity of adverse effects can be increased when Corticotropin is combined with Bendamustine. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Corticotropin is combined with Pralatrexate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Corticotropin is combined with Wortmannin. |
| Eribulin | The risk or severity of adverse effects can be increased when Corticotropin is combined with Eribulin. |
| Belimumab | The risk or severity of adverse effects can be increased when Corticotropin is combined with Belimumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Corticotropin is combined with Teriflunomide. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Corticotropin is combined with Carfilzomib. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Corticotropin is combined with Dimethyl fumarate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Corticotropin is combined with Obinutuzumab. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Corticotropin is combined with Vedolizumab. |